H-Index
79
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
16%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo



eISSN: 1643-3750

ZMapp: A New Cocktail of Monoclonal Antibodies with Much Promise in Containing the Current Epidemic of Ebola Virus Disease

Ihsan Al-Bayati, Mohamed Teleb, Kevin Lowder, Hasan J. Salameh

Department of Internal Medicine, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, TX, USA

Med Sci Rev 2015; 2:32-34

DOI: 10.12659/MSRev.894256

Available online:

Published: 2015-04-25


ABSTRACT: Supportive and preventive measures are the main strategy implemented by the health care organizations since there is no current approved medication to treat Ebola. From the emerging need for a solution that will help control, prevent, and/or treat Ebola virus disease, many therapies and vaccinations are currently being studied. ZMapp, which is a cocktail of monoclonal antibodies that target Ebola virus glycoprotein, has shown promising results in nonhuman primates and was recently approved in February 2015 for a clinical trial for safety and efficacy in patients in Liberia and the United States. Bringing a new medication with much hope to effectively treat Ebola virus disease may also enhance disease containment by providing an incentive for otherwise reluctant persons who fear they may have become infected to report themselves to local health authorities and seek medical treatment.

Keywords: Disease Outbreaks, Ebola Vaccines, Ebolavirus



Back